Antigenics, mal eine Betrachtung wert? - 500 Beiträge pro Seite

[Kelbi]

Nancy Zambell von INVESTools zitiert in ihrem "The Technologie Digest" Porter Stansberry, der Aktien des Pharmaunternehmens Antigenics zum Kauf empfiehlt. (WKN 934396) Stanberry meine, eine revolutionäre Behandlungsmethode gegen Krebs könne für ein Unternehmen großen Reichtum bedeuten. Die Behandlungsmethode, die von Antigenics entwickelt werde verwende so genannte "Hitzeschock-Proteine", die dem Immunsystem übermittelten, was die Zerstörung einer bestimmten Zelle verursacht habe. Diese Proteine würden von Krebszellen normalerweise nicht abgesondert, weshalb das Immunsystem den angreifenden Krebs nicht erkennen könne. Eine neue Behandlungsmethode von Antigenics umgehe aber dieses Problem und versetze das Immunsystem in die Lage, Gegenmaßnahmen wie Killer-T-Zellen zu ergreifen. Stansberry meine, die Impfstoffe von Antigenics repräsentierten für viele Patienten innerhalb der nächsten 3-4 Jahre die beste Hoffnung. So habe z.B. die Hälfte von 38 Patienten mit unheilbarem Nierenkrebs zwei Jahre nach der Behandlung überlebt, während die Überlebensrate normalerweise nur bei 10% liege. Antigenics habe auch ein Gerichtsverfahren gegen einen europäischen Konkurrenten gewonnen, der versucht habe seine eigene Art der Hitzeschock-Proteintherapie zu patentieren. Damit habe Antigenics seine Vormachtstellung auf diesem gebiet untermauern können, weshalb derzeit viele Insider größere Mengen der Aktie zukauften. Das neue, erweiterbare Labor von Antigenics könne derzeit 10.000 Impfungen pro Jahr herstellen, wobei das Unternehmen diese Kapazität binnen sech Monaten auf das Doppelte erweitern könne. Die Kosten einer kompletten Behandlung lägen für Antigenics bei 1.800 US-Dollar, woraus sich für Stansberry eine Bruttomarge von 90% errechne, wenn das Produkt zu einem ähnlichen Preis wie vergleichbare Behandlungen von Genentech und Imclone von 18.000 - 20.000 US-Dollar auf den markt komme. Bei einem Marktanteil von nur 20% bei neuen Nierenkrebsfällen würde das laut Stansberry im Jahr 2004 einen Nettogewinn von 75 Mio. US-Dollar ergeben und sollten alle 7 angestrebten Krebsarten bis zum Jahr 2006 behandelt werden können, könnte der Nettogewinn/Jahr 1 Mrd US-Dollar betragen. Aus diesem Grund empfehle Porter Stansberry, Aktien von Antigenics zu kaufen.






Quelle: AKTIENCHECK.DE AG

Ich krieg den Chart einfach nicht rein aber Ihr könnt ihn euch ja selber ansehen.

Also ich denke, könnte ein interessantes Unternehmen sein,oder?

[Kelbi]

Da sich ja offensichtlich keiner für Antigenics zu interessieren scheint, hier der Link zur Produktpipeline auf der Homepage, vieleicht ändert das ja eure Meinung, würde mich über eine rege Disskusion freuen.

Gruß

Kelbi

http://www.antigenics.com/products01.html

[Kelbi]

So, diese Meldung dürfte kurfristig den Kurs erstmal drücken, aber bei der doch etwas dünnen Kapitaldecke war das ja eigentlich über kurz oder lang zu erwrten. Auf der Watchlist steht Antigenics bei mir jedenfalls erstmal ganz weit oben.

Gruß

Kelbi

Antigenics files $100 mln debt, stock shelf offering
WASHINGTON, Nov 27 (Reuters) - Antigenics Inc. (NasdaqNM:AGEN - news), whose technology seeks to boost the immune system to help fight cancer and other diseases, filed on Tuesday with the Securities and Exchange Commission to periodically sell up to $100 million in debt securities and common and preferred stock.

The New York City-based company plans to use the net proceeds for general corporate purposes, which may include working capital, capital expenditures, acquisitions of new technologies and investments, it said in the shelf registration filing.

Under such a filing, a company may sell securities from time to time in one or more separate offerings in amounts, at prices and on terms to be determined at the time of sale.

[puhvogel]

Ich warte auch nur auf den richtigen Einstiegszeitpunkt.

[Kelbi]

@puhvogel

Ist zwar ne ziemlich hypothetische Frage, aber wonach richtest Du Dich beim Einstieg?

Bei Antigenics würde sich meiner Meinung nach z.B. ein Stop Buy bei ca. 16,50-17 USD anbieten, oder?(rein Charttechnisch und unter Berücksichtigung versch. Indikatoren)

[puhvogel]

Wenn ich die jetzige Verwässerung einberechne, komme ich auf einen Wunsch-Einstiegskurs von etwa 12,80 €.

[Kelbi]

Klingt auch nicht schlecht:

Antigenics` Immune Adjuvant Shows Benefit In Preventing Malaria In Randomized Trial
NEW YORK, Dec. 14 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN - news) announced today the publication of clinical results of a malaria vaccine containing the company`s immune response enhancer, QS-21, which showed significant protection against the most widespread and dangerous forms of malaria. The study, published in the December 8 issue of The Lancet, is titled ``Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial.``

GlaxoSmithKline Biologicals (GSKB) is developing the vaccine for the treatment of malaria. Currently named RTS,S/AS02, it is produced by combining a malaria antigen with an adjuvant formulation that contains QS-21.

In the 250 men who completed the study in The Gambia, West Africa, the vaccine was found safe and immunogenic. It induced strong antibody responses to circumsporozoite protein and strong T-cell responses. This is the first pre-erythrocytic vaccine to show significant protection against natural P. falciparum.

The effectiveness of QS-21 has been evaluated in approximately 50 Phase I, II and III trials involving more than 3,000 patients. QS-21 has been shown to enhance the quality and quantity of the immune response to a variety of antigens including those associated with malaria. Specifically, in a study published in the New England Journal of Medicine, January 9, 1997, researchers from the Walter Reed Army Institute of Research in Washington, DC and SmithKline Beecham Biologicals found that the RTS,S vaccine combined with QS-21 protected against experimental challenge with P falciparum parasites in six of seven patients. The RTS,S vaccine alone protected only two of seven patients and the vaccine combined with alum (another adjuvant) only protected one patient of eight from contracting malaria.

QS-21 is also a key component in several other vaccines under development including Elan/American Home Product`s AN-1792 for Alzheimer`s Disease and VaxGen`s product for HIV.

Malaria is an acute and chronic parasitic disease caused by the protozoan parasites of the genus Plasmodium and spread by the bite of the female Anopheles mosquito. P falciparum is the most widespread and dangerous of the malaria parasites, as it is responsible for most of the severe forms of the disease, as well as the majority of the deaths. The incidence of malaria is estimated to be between 300 and 500 million clinical cases each year. Furthermore, malaria accounts for more than 1 million deaths each year. In particular, malaria is a significant cause of infant and juvenile mortality, causing approximately 800,000 deaths in children under the age of five annually. Although the disease was previously widespread, malaria now occurs primarily in Africa, Asia and South and Central America.

[Kelbi]

Und wieder News, dem Kurs hilfts leider nicht...

Antigenics Adds Patent to Its Dominant Position in Heat Shock Protein Immunotherapy
NEW YORK, Dec. 18 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN - news) today announced the issuance of another U.S. patent covering the use of heat shock proteins (HSPs) in activating the immune system to treat cancer and infectious diseases.

Antigenics is the only company with issued patents on the therapeutic use of HSP-antigen complexes to treat such diseases. The current patent is the 21st licensed by the company and specifically covers the use of HSP-antigen complexes in combination with dendritic cells, a type of immune cell that is crucial for the activation of immune responses.

Antigenics` pioneering HSP technology, works by programming relevant immune pathways that are necessary to target cancers and viruses, such as HIV and herpes, as well as intracellular bacteria such as tuberculosis. HSP molecules -- described in a recent Nature Immunology publication as the immune system`s ``Swiss army knife`` -- have been demonstrated to activate CD8+ and CD4+ lymphocytes; induce innate immune response including cytokine secretion; and induce maturation of dendritic cells. The company`s products that are based on HSP technology include, Oncophage®, which is being tested in seven types of cancer including late stage clinical trials for kidney cancer; and AG-702, designed to target the causative agent of genital herpes.

Antigenics` patent portfolio includes claims that cover therapeutic uses of HSPs noncovalently complexed to proteins or peptides, regardless of their sequence, including peptides with modifications in their natural sequence to include or substitute amino acids. The HSP complexes can be produced in a test tube or can be manufactured from natural sources including tumor cells or cells infected with viruses or bacteria. The portfolio also includes claims directed to therapeutic uses of HSPs noncovalently complexed to antigens that are not specified to be either proteins or peptides.

Antigenics develops treatments for cancers, serious infections, autoimmune disorders and degenerative disorders that are designed to be more effective and safer than current alternatives. The company`s core expertise is in immunology, cancer and personalized medicine. Antigenics` most advanced drugs in development include Oncophage®, a personalized cancer vaccine in Phase III development; ATRA-IV, a liposomal form of vitamin A used to treat lymphoma; and QS-21, a superior antibody adjuvant partnered with leading pharmaceutical companies in several advanced clinical programs. For more information about Antigenics visit http://www.antigenics.com.

.

SOURCE: Antigenics Inc.

[Kelbi]

Die guten Meldungen hören nicht auf, nur beim Kurs tut sich absolut nichts....

Antigenics Receives Milestone Payment from Elan Corporation for QS-21 Immune Adjuvant
NEW YORK, Dec. 19 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN - news) announced today that it has received a milestone payment from Elan Corporation (NYSE: ELN - news) for its leading immune-stimulating adjuvant, QS-21, the only adjuvant utilized in an experimental Alzheimer`s disease vaccine under clinical development by Elan and American Home Products (NYSE: AHP - news). The milestone payment was based on the advancement of the vaccine, known as ``AN-1792``, to a Phase IIA trial after the product showed positive results in Phase I studies.

Antigenics` QS-21 adjuvant -- a compound used in combination with vaccines to boost immune responses -- is one of the most widely used and well- characterized immune adjuvants under development. QS-21 is included in a variety of products being developed by the world`s leading pharmaceutical companies for hepatitis B, malaria, HIV, cancer, respiratory viruses and Alzheimer`s disease.

Elan and AHP are evaluating AN-1792 in a Phase IIA clinical study including about 375 patients with mild to moderate Alzheimer`s disease at sites in the United States and Europe. The study is designed to measure the immune response to beta amyloid peptide and assess the impact on a range of cognitive, physiological and biological markers of Alzheimer`s disease. AN- 1792 is widely seen as one of the most promising therapies under development for Alzheimer`s disease.

``We are very pleased with the progress of AN-1792 in Phase IIA clinical trials,`` said Jonathan Lewis, M.D., Ph.D., chief medical officer of Antigenics, ``QS-21 continues to be an important component of leading immunological products in the clinic, as well as an increasingly important product for Antigenics. With additional research programs focused on harnessing the immune system to fight diseases ranging from AIDS to potential bio-terrorism agents, QS-21`s role will continue to grow.``

Antigenics develops treatments for cancers, serious infections, and autoimmune and degenerative disorders that are designed to be more effective and safer than current alternatives. The Company`s core expertise is in immunology, cancer and personalized medicine. Antigenics` most advanced drugs in development include Oncophage®, a personalized cancer vaccine in Phase III development; ATRA-IV, a liposomal form of vitamin A used to treat lymphoma; and QS-21, a superior antibody adjuvant partnered with leading pharmaceutical companies in several advanced clinical programs. For more information about Antigenics visit http://www.antigenics.com.

This release contains forward-looking statements including statements regarding the potential for QS-21. Various factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include those predicting the timing of clinical trials, the efficacy of products, the availability of capital, and those factors described in the Company`s periodic filings with the Securities and Exchange Commission

SOURCE: Antigenics Inc.

[Kelbi]

Und wieder eine positive Meldung, die im Moment sang und klanglos verpuffen wird...

Antigenics` Oncophage(R) Cancer Vaccine Receives FDA Fast Track Designation for Melanoma
Second Fast Track Designation for Oncophage
NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Antigenics Inc. (Nasdaq: AGEN - news) announced today that the U.S. Food and Drug Administration (FDA) has granted the company`s personalized cancer vaccine, Oncophage® (HSPPC-96), Fast Track designation for the treatment of metastatic melanoma.

As a Fast Track product, the FDA will take appropriate actions to expedite the development and review of Oncophage. Last October, Oncophage received its first Fast Track designation -- for the treatment of renal cell carcinoma (kidney cancer) -- making it the first personalized cancer product to receive Fast Track designation from the FDA.

``This represents another milestone in a line of regulatory achievements for Oncophage,`` said Russell Herndon, President and Chief Operating Officer of Antigenics. ``We see this as a further indication of the potential value of Oncophage to treat cancer patients.``

Oncophage is the company`s flagship product and contains the ``antigenic fingerprint`` derived from each individual`s tumor. It is designed to reprogram the body`s immune system to target and destroy cancer cells. This precision is designed to leave healthy tissue unaffected and prevent the debilitating side effects associated with traditional cancer treatments. A Phase III study of Oncophage in metastatic melanoma will begin early this year; Phase III evaluation in kidney cancer is ongoing.

About Melanoma

According to the American Cancer Society, melanoma only accounts for about 4 percent of skin cancer cases, yet it causes about 79 percent of skin cancer deaths. It is estimated that in 2002, there will be almost 54,000 new cases of melanoma in the United States, and about 7,400 people will die of the disease. Current treatment options are limited to surgical removal, radiation therapy, chemotherapy, immune therapy or a combination of these treatments -- all of which are associated with significant adverse effects.

[Guru-Schreck]

08.04. 15:12
Biotechunternehmen mit neuem Medikament
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)

Das Biotechunternehmen Antigenics verkündete heute, daß Oncophage, ein experimentelles Krebsmedikament, vielversprechende Testergebnisse gezeigt habe. So werde das Immunsystem der Patienten durch die Flüssigkeit erheblich gestärkt und könne wirksam gegen Krebs ankämpfen. Vorbörslich steigen die Antigenics-Aktien aktuell um 50 Cents auf 13,75$.

[Kelbi]

Reuters Company News
Antigenics cancer treatment gets orphan drug status

NEW YORK, May 29 (Reuters) - Antigenics Inc. (NasdaqNM:AGEN - News) on Wednesday said the U.S. Food and Drug Administration has granted the company`s experimental cancer vaccine Oncophage (HSPPC-96) orphan drug status for the treatment of kidney cancer.

Oncophage is not yet being marketed. It is in Phase III clinical trials for renal cell carcinoma and malignant skin cancer and is awaiting FDA review.

Orphan drug status would give Antigenics market exclusivity in renal cell carcinoma -- the most common type of kidney cancer -- for seven years.

Patients who receive treatment with Oncophage undergo a partial or complete kidney removal, followed by weekly injections of the drug, which is designed to reprogram the body`s immune system to target and destroy cancer cells.

The orphan drug program is intended to encourage research, development and approval of products that affect fewer than 200,000 patients in the United States.

[t.1]

@Kelbi
da du dich mit antigenics vertraut gemacht hast,hier meine beiden fragen:
1. gibt es das produckt gp-21 bei antigenics noch? oder wurde es im januar eingestellt,oder an vaxgen weitergereicht.
2. was soll qs-21 für eine wirkung bei HIV haben ?
finde persönlich die pipeline gut und den einstiegskurs ideal .
für deine rückantwort im voraus danke.
t.1

[Kelbi]

@t1 Sorra das ich jetzt erst antworte aber im Moment wenig Zeit mich intensiv weiter mit AGEN zu beschäftigen.Vieleicht kann ja jemand hier im Board mal aushelfen....

Hier die neueste Meldung die auch den gestrigen Ansteig erklären dürfte. Erfahrungsgemäß dürfte dieser aber schnell wieder verpuffen. Watchlist ja aber kaufen im Moment nein, höchstens traden. Abwarten bis zum Bruch der Abwärtstrends und wann das passiert dazu wagt wohl keine eine Prognose im Moment...

Gruß

Kelbi

Antigenics drug gets orphan status for melanoma

NEW YORK, July 23 (Reuters) - Drug developer Antigenics Inc. (NasdaqNM:AGEN - News) said Tuesday the U.S. Food and Drug Administration has granted orphan drug status to its Oncophage cancer vaccine for the treatment of metastatic melanoma, giving the company potential market exclusivity for seven years.

Orphan drug status, which Oncophage received in May for the treatment of renal cell carcinoma, provides tax incentives for up to 50 percent of a company`s investment in U.S. clinical research, available funding to support clinical trials, and study design assistance.

The orphan drug program is intended to encourage research, development, and approval of products for diseases that affect fewer than 200,000 patients in the United States.

Antigen shares closed Monday at $7.91 a share.

[Kelbi]

Positive Phase II Results of Oncophage Cancer Vaccine in Melanoma Published in the Journal of Clinical Oncology
Monday October 14, 7:01 am ET


NEW YORK--(BUSINESS WIRE)--Oct. 14, 2002--Antigenics Inc. (Nasdaq: AGEN - News), the world leader in heat shock protein technology, today announced positive final results from a Phase II study of the company`s personalized cancer vaccine Oncophage® (HSPPC-96) in patients with metastatic melanoma.
ADVERTISEMENT


The study showed that treatment with Oncophage was associated with both immunological and clinical response--including two complete responses--and appeared generally safe and well tolerated. Results were published in the October 15 issue of the Journal of Clinical Oncology.

"This is one of the first reported studies demonstrating complete clinical responses without significant toxicities using a single agent in melanoma patients with extensive metastasis -- a stage of disease in which complete responses are extremely rare," said Jonathan Lewis, M.D., Ph.D., Chief Medical Officer of Antigenics. "The currently approved treatments such as interleukin 2 and dacarbazine tend to have associated toxicities, and have shown no survival benefit for patients with advanced melanoma. The combination of encouraging clinical and immunological response and lack of significant side effects in this study makes us very hopeful that Oncophage may become an effective alternative to today`s widely used therapies."

Based on proprietary heat shock protein technology, Oncophage is derived from each individual`s tumor and designed to capture the `antigenic fingerprint` of the patient`s particular cancer in order to reprogram the body`s immune system to target and destroy only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and prevent the debilitating side effects associated with traditional cancer treatments such as chemotherapy and radiation therapy.

The recently published Phase II study involved 39 evaluable patients with stage IV melanoma, most of whom had not responded to treatment with established therapies. All patients underwent surgery to remove tumor tissue, which was used to produce their personalized Oncophage vaccines. Surgery was followed by at least one cycle of Oncophage treatment (one injection weekly for four weeks) for all patients.

Of the 28 patients who had residual disease after surgery, two experienced complete clinical responses (complete disappearance of disease) after treatment with Oncophage. In addition, these two patients survived tumor-free for at least two more years after treatment, despite a median survival of only seven months for patients with stage IV melanoma. Furthermore, an additional three patients who had tumor remaining after surgery experienced extended disease stabilization (five to nine months) after Oncophage treatment. Of the 11 patients rendered disease-free by surgery, three experienced long-term disease-free survival (eight to 21 months).

In addition to the clinical responses observed in the trial, researchers also evaluated a portion of the patients for immunological response to Oncophage vaccination. Of the 23 patients tested, significant increases in melanoma-specific T-cell activity were observed in 11 patients--five of whom also experienced complete response or long-term disease stabilization.

"These results suggest a correlation between Oncophage-induced immunological activity and clinical response, which is an important proof of principle for Oncophage and its potential to treat a wide range of cancers," said Giorgio Parmiani, M.D., Istituto Nazionale Tumori in Milan, Italy, and lead investigator of the study.

Already in Phase III clinical trials for metastatic melanoma and kidney cancer, other clinical research evaluating Oncophage includes studies in several other cancers such as lymphoma, colorectal, pancreatic and gastric cancers. Oncophage has been granted fast track designation and orphan drug status from the U.S. Food and Drug Administration (FDA) in both metastatic melanoma and kidney cancer.